Creative Medical Technology Holdings Inc (CELZ)

[docprep]

This is all that matters.......but don't trust me or anyone on the blog. Do you own DD please. The FDA does not regulate medical procedures performed by qualified and licensed doctors. CaverStem has the only clinically proven procedure to treat Erectile Dysfunction with adult stem cells in the US. CaverStem ONLY uses your own adult stem cells (not Embryonic stem cells) and they are not altered, manipulated or stored. Therefore, FDA does not object to these procedures. CaverStem has been shown to be effective even in patients who do not respond to PDE5 inhibitors. CaverStem is safe. Several doctors in the US have been vetted and signed and are now OPEN and treating patients (Doctors Gershman, Said, Bieri, Liu, Narayan, Niemczyk and Sanderson). Currently you can make an appointment any of those locations along with Dr. Antonini in Rome, Italy. CELZ added physicians in Hawaii (Sanderson), California, Ohio, Texas and Tennessee (to be named soon) and CELZ will continually add the new physicians to the CaverStem™ website as they come aboard. To speed up new physician training due to demand, CELZ added additional medical personnel to travel to each physicians office to train. Due to the increased international demand and to compliment the existing relationship with Scott Shea, Thomas Bianchi has joined the company as the international sales representative. Over 50 domain names have been registered showing that MANY more doctors are being vetted or have shown interest. These includes MANY cities and states in the USA, and now we KNOW there are domains registered in Russia (PromoMed, Dr. Pushkar), Germany, France, Switzerland (Alto Uro, Dr. Bachmann) and Austria. CaverStem has begun a series of mailer and email campaigns introducing the CaverStem procedure to licensed physicians in the areas of urology, sexual function and plastic surgery. This campaign which will be expanded on a monthly basis with follow up mailers and emails and calls from our sales representatives. It's the goal to reach out to a minimum of 2500 new physicians each month by these methods. CaverStem reported good replies from the January emails. CaverStem has also increased its online presence on Social Media and by placing banner advertising on websites and search engines attracting the active male. They are currently scripting television commercials which will be edited to direct patients to each physician in their area. U.S. and international agreements have been reached for exclusive distribution rights for the FDA approved Generation 2 bone marrow harvest technology which has been used with multiple ED patients with excellent results, however Government exemptions are required for the ongoing import of the device in Russia. This is a slow and tedious process in getting approval, therefore CELZ progress has been delayed in Russia. Your DD will show that Dr. Gershman has been performing the procedure with EXCELLENT results…Up to 90% success rate, even in difficult patients. CELZ has received positive feedback from treating physicians of a 70% to 90% efficacy in their patients. Obviously results differ depending on the age and health of the patient and cause and severity of their erectile dysfunction. A one-year trial has concluded and will PROVE the same results and you can watch it here; https://clinicaltrials.gov/ct2/show/NCT03699943?recrs=deghi&fund=2&lupd_s=09%2F27%2F2018&lupd_d=14 Please review this. CELZ is working on their paper for publication. This is ongoing and in compliance with contractual obligations. Once the paper has been approved by The Journal of Translational Medicine and a publication date advised, shareholders will be updated. Additionally, CELZ has designed an electronic patient registry that is intended to include data from the clinical trial, data from treating physicians using centrifuge technology with a 30cc to 60cc bone marrow aspiration and the second generation, needle only. Revenue has now started, CMTH is cash flowing. Additional physicians are scheduled for training, patients are being treated and revenues are being generated and increasing each month. CMTH anticipates reaching financial self-sufficiency by revenues from sales in 2019. CMTH has Institutional Investors now, slowing dilution and providing much better terms as CMTH completes the commercialization phase. The most recent notes that were issued in 2018 were renegotiated providing cash for operations. CaverStem signed with PatientGain to redesigning the website for the anticipated HUGE volume of traffic CaverStem will generate. This has generated many calls to the vetted doctors. CMTH has started commercializing and scheduling patients for the FemCelz procedure for the treatment of female sexual dysfunction using stem cells from the patient's own bone marrow. Many of the existing CaverStem affiliated physician's will also treat female patients for sexual function and we anticipate that they will be the leaders in progressing the FemCelz program. CMTH anticipates acquiring the Virility Centers of America brand from affiliate company Creative Medical Health, Inc. The use of the Virility Centers brand is related to male and female wellness clinics, including sexual function (CaverStemTM and FemCelzTM), incontinence and infertility. This brand will compliment the CaverStem and FemCelz brands. CaverStem and FemCelz are just TWO of SEVERAL patents held by CMTH. 4 NEW patents were applied for in 2018. Gershman and Ichim have already successfully commercialized Medistem. CaverStem, FemCelz, StemSpine & AmnioStem have all be TRADEMARKED CaverStem is now a REGISTERED TRADEMARK. Caverstem® We KNOW Caverstem® + FemCelz + StemSpine + AmnioStem = NASDAQ PLEASE